Cholangiocarcinoma producing parathyroid hormone-related peptide treated with chemoradiation using gemcitabine and S-1.
Although chemotherapy for cholangiocellular carcinoma (CCC) is administered to those patients who are inoperable, the results are largely disappointing, especially for CCC producing parathyroid hormone-related peptide (PTHrP). We encountered a 43-year-old man with hypercalcemia due to PTHrP secretion of CCC. As the tumor was inoperable, we treated him with gemcitabine (GEM), S-1 and radiation. The tumor size was reduced 55% and the serum PTHrP level decreased markedly after the chemoradiotherapy. Although the patient died after 14 months, this case clearly suggests that the combined chemoradiotherapy of GEM, S-1 and radiation, may be useful for the treatment of CCC producing PTHrP.
Yamada
Masayoshi
M
Department of Gastroenterology, Kanazawa Medical University, Ishikawa. m-yamada@kanazawa-med.ac.jp
Shiroeda
Hisakazu
H
Shiroeda
Shoko
S
Sato
Katsuaki
K
Arisawa
Tomiyasu
T
Tsutsumi
Mikihiro
M
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D001650:Bile Duct Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D001653:Bile Ducts, Intrahepatic; D018281:Cholangiocarcinoma / Q000188:drug therapy* / Q000378:metabolism; D003131:Combined Modality Therapy; D004338:Drug Combinations; D006801:Humans; D008297:Male; D010094:Oxonic Acid / Q000627:therapeutic use; D044162:Parathyroid Hormone-Related Protein / Q000378:metabolism; D018714:Radiotherapy, Adjuvant; D005641:Tegafur / Q000627:therapeutic use
D004338:Drug Combinations; D044162:Parathyroid Hormone-Related Protein; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid